Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies
Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineag...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Tímár, J [verfasserIn] Udvarhelyi, N [verfasserIn] Bánfalvi, T [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Science Ltd ; 2004 |
|---|
| Schlagwörter: |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2004 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: Histopathology - Oxford [u.a.] : Wiley-Blackwell, 1977, 44(2004), 2, Seite 0 |
| Übergeordnetes Werk: |
volume:44 ; year:2004 ; number:2 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1111/j.1365-2559.2004.01800.x |
|---|
| Katalog-ID: |
NLEJ242760716 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242760716 | ||
| 003 | DE-627 | ||
| 005 | 20210707163701.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s2004 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/j.1365-2559.2004.01800.x |2 doi | |
| 035 | |a (DE-627)NLEJ242760716 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a Tímár, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| 264 | 1 | |a Oxford, UK |b Blackwell Science Ltd |c 2004 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. | ||
| 533 | |d 2004 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2004|||||||||| | ||
| 650 | 4 | |a immunohistochemistry | |
| 700 | 1 | |a Udvarhelyi, N |e verfasserin |4 aut | |
| 700 | 1 | |a Bánfalvi, T |e verfasserin |4 aut | |
| 700 | 1 | |a Gilde, K |4 oth | |
| 700 | 1 | |a Orosz, Zs |4 oth | |
| 773 | 0 | 8 | |i In |t Histopathology |d Oxford [u.a.] : Wiley-Blackwell, 1977 |g 44(2004), 2, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243927045 |w (DE-600)2006447-0 |x 1365-2559 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2004 |g number:2 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2004 |e 2 |h 0 | ||
| author_variant |
j t jt n u nu t b tb |
|---|---|
| matchkey_str |
article:13652559:2004----::cuayfhdtriainf10poenxrsinnainnmlnmuigoy |
| hierarchy_sort_str |
2004 |
| publishDate |
2004 |
| allfields |
10.1111/j.1365-2559.2004.01800.x doi (DE-627)NLEJ242760716 DE-627 ger DE-627 rakwb Tímár, J verfasserin aut Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| immunohistochemistry Udvarhelyi, N verfasserin aut Bánfalvi, T verfasserin aut Gilde, K oth Orosz, Zs oth In Histopathology Oxford [u.a.] : Wiley-Blackwell, 1977 44(2004), 2, Seite 0 Online-Ressource (DE-627)NLEJ243927045 (DE-600)2006447-0 1365-2559 nnns volume:44 year:2004 number:2 pages:0 http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 44 2004 2 0 |
| spelling |
10.1111/j.1365-2559.2004.01800.x doi (DE-627)NLEJ242760716 DE-627 ger DE-627 rakwb Tímár, J verfasserin aut Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| immunohistochemistry Udvarhelyi, N verfasserin aut Bánfalvi, T verfasserin aut Gilde, K oth Orosz, Zs oth In Histopathology Oxford [u.a.] : Wiley-Blackwell, 1977 44(2004), 2, Seite 0 Online-Ressource (DE-627)NLEJ243927045 (DE-600)2006447-0 1365-2559 nnns volume:44 year:2004 number:2 pages:0 http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 44 2004 2 0 |
| allfields_unstemmed |
10.1111/j.1365-2559.2004.01800.x doi (DE-627)NLEJ242760716 DE-627 ger DE-627 rakwb Tímár, J verfasserin aut Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| immunohistochemistry Udvarhelyi, N verfasserin aut Bánfalvi, T verfasserin aut Gilde, K oth Orosz, Zs oth In Histopathology Oxford [u.a.] : Wiley-Blackwell, 1977 44(2004), 2, Seite 0 Online-Ressource (DE-627)NLEJ243927045 (DE-600)2006447-0 1365-2559 nnns volume:44 year:2004 number:2 pages:0 http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 44 2004 2 0 |
| allfieldsGer |
10.1111/j.1365-2559.2004.01800.x doi (DE-627)NLEJ242760716 DE-627 ger DE-627 rakwb Tímár, J verfasserin aut Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| immunohistochemistry Udvarhelyi, N verfasserin aut Bánfalvi, T verfasserin aut Gilde, K oth Orosz, Zs oth In Histopathology Oxford [u.a.] : Wiley-Blackwell, 1977 44(2004), 2, Seite 0 Online-Ressource (DE-627)NLEJ243927045 (DE-600)2006447-0 1365-2559 nnns volume:44 year:2004 number:2 pages:0 http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 44 2004 2 0 |
| allfieldsSound |
10.1111/j.1365-2559.2004.01800.x doi (DE-627)NLEJ242760716 DE-627 ger DE-627 rakwb Tímár, J verfasserin aut Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies Oxford, UK Blackwell Science Ltd 2004 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. 2004 Blackwell Publishing Journal Backfiles 1879-2005 |2004|||||||||| immunohistochemistry Udvarhelyi, N verfasserin aut Bánfalvi, T verfasserin aut Gilde, K oth Orosz, Zs oth In Histopathology Oxford [u.a.] : Wiley-Blackwell, 1977 44(2004), 2, Seite 0 Online-Ressource (DE-627)NLEJ243927045 (DE-600)2006447-0 1365-2559 nnns volume:44 year:2004 number:2 pages:0 http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 44 2004 2 0 |
| source |
In Histopathology 44(2004), 2, Seite 0 volume:44 year:2004 number:2 pages:0 |
| sourceStr |
In Histopathology 44(2004), 2, Seite 0 volume:44 year:2004 number:2 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
immunohistochemistry |
| isfreeaccess_bool |
false |
| container_title |
Histopathology |
| authorswithroles_txt_mv |
Tímár, J @@aut@@ Udvarhelyi, N @@aut@@ Bánfalvi, T @@aut@@ Gilde, K @@oth@@ Orosz, Zs @@oth@@ |
| publishDateDaySort_date |
2004-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243927045 |
| id |
NLEJ242760716 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242760716</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707163701.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2559.2004.01800.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242760716</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tímár, J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Udvarhelyi, N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bánfalvi, T</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gilde, K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orosz, Zs</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Histopathology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1977</subfield><subfield code="g">44(2004), 2, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927045</subfield><subfield code="w">(DE-600)2006447-0</subfield><subfield code="x">1365-2559</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:44</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">44</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
Tímár, J |
| spellingShingle |
Tímár, J misc immunohistochemistry Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| authorStr |
Tímár, J |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243927045 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-2559 |
| topic_title |
Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies immunohistochemistry |
| publisher |
Blackwell Science Ltd |
| publisherStr |
Blackwell Science Ltd |
| topic |
misc immunohistochemistry |
| topic_unstemmed |
misc immunohistochemistry |
| topic_browse |
misc immunohistochemistry |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
k g kg z o zo |
| hierarchy_parent_title |
Histopathology |
| hierarchy_parent_id |
NLEJ243927045 |
| hierarchy_top_title |
Histopathology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243927045 (DE-600)2006447-0 |
| title |
Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| ctrlnum |
(DE-627)NLEJ242760716 |
| title_full |
Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| author_sort |
Tímár, J |
| journal |
Histopathology |
| journalStr |
Histopathology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
2004 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Tímár, J Udvarhelyi, N Bánfalvi, T |
| container_volume |
44 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
Tímár, J |
| doi_str_mv |
10.1111/j.1365-2559.2004.01800.x |
| author2-role |
verfasserin |
| title_sort |
accuracy of the determination of s100b protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| title_auth |
Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| abstract |
Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. |
| abstractGer |
Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. |
| abstract_unstemmed |
Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
2 |
| title_short |
Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies |
| url |
http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x |
| remote_bool |
true |
| author2 |
Udvarhelyi, N Bánfalvi, T Gilde, K Orosz, Zs |
| author2Str |
Udvarhelyi, N Bánfalvi, T Gilde, K Orosz, Zs |
| ppnlink |
NLEJ243927045 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1111/j.1365-2559.2004.01800.x |
| up_date |
2024-07-06T03:05:59.052Z |
| _version_ |
1803797302139158528 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242760716</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210707163701.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s2004 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1111/j.1365-2559.2004.01800.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242760716</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Tímár, J</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Accuracy of the determination of S100B protein expression in malignant melanoma using polyclonal or monoclonal antibodies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Science Ltd</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Aims : To compare the routinely used polyclonal anti-S100 and a mouse monoclonal anti-S100B antibody for their accuracy in the detection of the S100B expression profile (pattern and intensity) in a series of 67 primary (n = 37) and lymph node metastatic (n = 30) melanoma tissues. S100B is the lineage marker of malignant melanoma. Antibodies routinely used for melanoma diagnosis are not necessarily specific for this protein. Furthermore, clinical monitoring of melanoma progression is mostly based on the determination of serum S100B protein levels without knowing the actual expression level in the primary and/or metastatic tissue.Methods and results : The profile of expression patterns (focal, heterogenous and diffuse) as well as intensity ranges (+, ++ and +++) were similar for the two antibodies in melanoma tissues. However, comparison of the patterns and intensities on the basis of individual cases revealed a high frequency of discrepancies (50.7 and 58.2%, respectively). Severe discrepancy between the two antibodies in the determination of the S100B protein expression pattern (focal versus diffuse or focal versus heterogeneous) was relatively frequent; 13.4 and 11.9%, respectively. Furthermore, a similar rate of severe discrepancy was observed between the two antibodies in the determination of the intensity of S100B expression levels (+ versus +++ or + versus ++); 19.4 and 8.9%, respectively. Separate analysis of the primary tumours and metastases gave similar results.Conclusion : For the accurate determination of S100B protein expression in malignant melanoma it is highly recommended that a monospecific antibody is used.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2004</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2004||||||||||</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">immunohistochemistry</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Udvarhelyi, N</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bánfalvi, T</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gilde, K</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Orosz, Zs</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Histopathology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1977</subfield><subfield code="g">44(2004), 2, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927045</subfield><subfield code="w">(DE-600)2006447-0</subfield><subfield code="x">1365-2559</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:44</subfield><subfield code="g">year:2004</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1111/j.1365-2559.2004.01800.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">44</subfield><subfield code="j">2004</subfield><subfield code="e">2</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.401434 |